Icon Plc (NASDAQ: ICLR) is a contract research organization (“CRO”). In the Q3 2024 letter, I highlighted our investment in Medpace (MEDP) another CRO that directly competes with Icon.

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to ...

A month has gone by since the last earnings report for Icon PLC (ICLR). Shares have lost about 8.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 109 locations in 53 countries as at March 31, 2023. For further information about ICON, visit: www.iconplc.com.

Investors might want to bet on Icon PLC (ICLR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 106 locations in 53 countries as at September 30, 2023. For further information about ICON, visit: www.iconplc ...